Overview

This trial is active, not recruiting.

Condition solid tumor or lymphoma
Treatment lenvatinib
Phase phase 1
Target VEGF
Sponsor Eisai Inc.
Start date July 2005
End date June 2009
Trial size 87 participants
Trial identifier NCT00121719, E7080-E044-101

Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
lenvatinib E7080
Lenvatinib tablets taken orally, once daily.

Primary Outcomes

Measure
The maximum tolerated dose as defined by an incidence of dose limiting toxicity of no more than 17% (one in six).
time frame: First four weeks of treatment.

Secondary Outcomes

Measure
Tumor assessments should be performed at screening and at appropriate clinical intervals as determined by the investigator.
time frame: At screening, every 2 cycles and where clinically indicated.
The best response to treatment with lenvatinib, as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST), will be documented.
time frame: Every 2 cycles.
Blood samples taken to determine the pharmacokinetic profile of lenvatinib.
time frame: Blood samples taken from patient on Days 1, 8, 15 and 22 of Cycle 1 and on Day 1 of all other cycles.
Blood samples taken to identify pharmacodynamic biomarkers of lenvatinib.
time frame: Blood samples taken from patient on Days 1, 15 and 22 of Cycle 1 and on Day 1 of all other cycles.
Adverse Events (AEs) recorded to explore the safety and tolerability of lenvatinib.
time frame: All AEs are recorded in case report forms on an ongoing basis throughout the study and constantly monitored and assessed.

Eligibility Criteria

Male or female participants at least 18 years old.

INCLUSION CRITERIA: Patients must meet all of the inclusion criteria outlined below in order to be eligible to participate in the study: 1. Patients with histologically and/or cytologically confirmed solid tumor or lymphoma who are resistant/refractory to approved therapies or for whom no appropriate therapies are available. 2. All previous treatment (including surgery and radiotherapy) must have been completed at least four weeks prior to study entry and any acute toxicities must have resolved. 3. Aged greater than or equal to 18 years. 4. Karnofsky performance status greater than or equal 70%. 5. Written informed consent to participate in the study. EXCLUSION CRITERIA: Patients with the following characteristics will not be eligible for the study: 1. Brain tumors or brain or leptomeningeal metastases. 2. Any of the following laboratory parameters: 1. hemoglobin less than 9 g/dl (5.6 mmol/L) 2. neutrophils less than 1.5 x 10^9/L 3. platelets less than 100 x 10^9/L 4. serum bilirubin greater than 25 micro-mol/l (1.5 mg/dl) 5. other liver parameters greater than 3 x the upper limit of normal (ULN) 6. serum creatinine greater than 1.5 x ULN or creatinine clearance less than 60 ml/minute 3. Uncontrolled infections. 4. Clinically significant cardiac impairment or unstable ischemic heart disease including a myocardial infarction within six months of study start. 5. Any treatment with investigational drugs within 30 days before the start of the study. 6. Pregnancy or lactation (all women of childbearing potential must have a negative pregnancy test before inclusion in the study; post-menopausal women must be amenorrheic for at least 12 months). Female patients of childbearing potential must use adequate contraceptive protection, defined as two forms of contraception, one of which must be a barrier method. 7. Fertile males not willing to use contraception or whose female partners are not using adequate contraceptive protection. 8. History of alcoholism, drug addiction, or any psychiatric or psychological condition which, in the opinion of the investigator, would impair study compliance. 9. Legal incapacity. 10. Centrally located or squamous cell carcinoma of the lung. 11. Proteinuria greater than 1+ on bedside testing. 12. History of gastrointestinal malabsorption. 13. Surgery involving gastro- and/or intestinal anastomosis within four weeks of study start. 14. Patients with bleeding or thrombotic disorders. 15. Patients using therapeutic dosages of anticoagulants. 16. Poorly controlled hypertension (defined as a change in hypertensive therapy within three months of study start) or patients diagnosed with hypertension (defined as a repeat blood pressure measurement of 160/90 mmHg or higher) at screening.

Additional Information

Official title An Open Label Phase I Dose Escalation Study Of E7080
Description This is an open-label, non-randomized, dose escalation study. Patients will be treated with lenvatinib once daily. Each four-week treatment period will be considered to be one treatment cycle. The selection of subsequent dose levels will be performed according to an accelerated design: Although initially 3 patients per dose level will be entered, the next dose level can be opened for patient accrual after only the first patient in the previous cohort completes Cycle 1 with no drug-related toxicity greater than grade 1 (except alopecia, lymphopenia and anemia).
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Eisai Inc..